Checkpoint Inhibitor-Induced Colitis
- PMID:31922959
- DOI: 10.14309/ajg.0000000000000497
Checkpoint Inhibitor-Induced Colitis
Abstract
Immune checkpoint inhibitors have revolutionized treatment and overall survival for several different types of cancer. Antibodies to cytotoxic T-lymphocyte-associated protein 4 and to programmed cell death protein 1 and its ligand enhance cytotoxic T-cell survival, thus augmenting antitumor action and consequently inducing immune-related adverse events, of which the most relevant is diarrhea and colitis. This review compiles recent data on pathophysiology, clinical manifestations, and treatment of immune-mediated colitis (IMC). The pathogenesis of IMC is not completely understood, but recent studies have focused on the role of regulatory T cells and interactions with the gut microbiome. While sharing similarities with inflammatory bowel disease, IMC is considered a distinct form of colitis with acute onset and rapid progression leading to potential complications including bowel perforation and death. Prompt recognition and management of IMC is imperative for optimal outcomes. Although prospective clinical trials are lacking to guide therapy, recent guidelines recommend early endoscopic evaluation to establish the diagnosis and prompt initiation of corticosteroids. Response to first-line therapy should be assessed early to determine the need of escalation to biologic agents. With treatment, most patients will experience full resolution of symptoms, and subsequent rechallenge with anti-programmed cell death protein 1 or anti-programmed death-ligand 1 inhibitors can be considered.
Comment in
- Checkpoint Inhibitor-Induced Colitis.Thomas AS, Wang Y.Thomas AS, et al.Am J Gastroenterol. 2020 Aug;115(8):1301-1302. doi: 10.14309/ajg.0000000000000739.Am J Gastroenterol. 2020.PMID:32756260No abstract available.
Similar articles
- Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis.Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y.Abu-Sbeih H, et al.J Immunother Cancer. 2019 Apr 2;7(1):93. doi: 10.1186/s40425-019-0577-1.J Immunother Cancer. 2019.PMID:30940209Free PMC article.
- [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].Papouin B, Mussini C, De Martin E, Guettier C.Papouin B, et al.Ann Pathol. 2018 Dec;38(6):338-351. doi: 10.1016/j.annpat.2018.07.005. Epub 2018 Aug 22.Ann Pathol. 2018.PMID:30143243Review.French.
- Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.Reddy HG, Schneider BJ, Tai AW.Reddy HG, et al.Clin Transl Gastroenterol. 2018 Sep 19;9(9):180. doi: 10.1038/s41424-018-0049-9.Clin Transl Gastroenterol. 2018.PMID:30228268Free PMC article.Review.
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.De Martin E, et al.J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.J Hepatol. 2018.PMID:29427729
- Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE.Guerrero E, et al.Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4.Eur J Cancer. 2019.PMID:30954881No abstract available.
Cited by
- A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors.Lessomo FYN, Mandizadza OO, Mukuka C, Wang ZQ.Lessomo FYN, et al.Eur J Med Res. 2023 Nov 8;28(1):495. doi: 10.1186/s40001-023-01464-1.Eur J Med Res. 2023.PMID:37941006Free PMC article.Review.
- Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review.Schiepatti A, Premoli A, Maimaris S, Rizzo M, Marples M, Villani L, Scott N, Sottotetti F, Sanders DS, Biagi F, Donnellan C.Schiepatti A, et al.Drugs Context. 2022 Oct 21;11:2022-6-3. doi: 10.7573/dic.2022-6-3. eCollection 2022.Drugs Context. 2022.PMID:36339292Free PMC article.
- Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?Herlihy N, Feakins R.Herlihy N, et al.United European Gastroenterol J. 2022 Jun;10(5):451-464. doi: 10.1002/ueg2.12242. Epub 2022 May 28.United European Gastroenterol J. 2022.PMID:35633273Free PMC article.Review.
- Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review.Mallio CA, Bernetti C, Cea L, Buoso A, Stiffi M, Vertulli D, Greco F, Zobel BB.Mallio CA, et al.Curr Oncol. 2023 May 3;30(5):4700-4723. doi: 10.3390/curroncol30050355.Curr Oncol. 2023.PMID:37232813Free PMC article.Review.
- Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation.Chulkina M, Beswick EJ, Pinchuk IV.Chulkina M, et al.Int J Mol Sci. 2020 Dec 1;21(23):9165. doi: 10.3390/ijms21239165.Int J Mol Sci. 2020.PMID:33271941Free PMC article.Review.
References
- Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015;112(19):6140–5.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54.
- Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315(15):1600–9.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373(17):1627–39.
- Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23(35):8968–77.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials